Bucagel

Quick links to important sections

Bucagel

Selected form

Treatment option: Pain, Teething Pain, Fever, Dental

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bucagel

Bucagel is defined by several core properties: its active ingredient is Choline Salicylate; its form is an oromucosal gel; its pharmacological class is topical non-steroidal anti-inflammatory drug (NSAID) and analgesic; its common use is the relief of localized oral discomfort; and its origin is a synthetic compound. This pharmaceutical product is a specialized topical preparation formulated for application to the mucous membranes inside the mouth, distinguishing it from general oral pain relief liquids.

Bucagel: Definition and Pharmaceutical Class

This proprietary formulation is based on the single active ingredient, Choline Salicylate (INN), a salicylate derivative classified as a non-steroidal anti-inflammatory drug (NSAID) with prominent analgesic properties. Salicylates provide localized pain relief, meaning the medicine is clinically recognized for its ability to reduce both pain signals and inflammation at the specific application site.

The medicine's identity as a topical NSAID means it is designed for local action, a key differentiating factor that minimizes the systemic exposure associated with tablets, concentrating its analgesic and anti-inflammatory effects within the oral cavity.

Composition, Form, and General Purpose

The composition consists solely of the active ingredient, Choline Salicylate, embedded within an aqueous gel matrix. This oromucosal gel is the specialized dosage form required for effective adherence and prolonged contact with the moist oral tissues, allowing the synthetic compound to perform its function. The brand is often targeted toward the relief of localized pain, such as the discomfort associated with irritation from dental appliances.

The general purpose of Bucagel is to provide focused, reliable relief from pain and inflammation affecting the oral cavity. Topical salicylates provide symptomatic relief for pain associated with the oral mucosa. This analgesic and anti-inflammatory capability is complemented by a mild antiseptic component often included in the formulation, which aids in overall mucosal soothing.

What side effects are possible with Bucagel?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Choline Salicylate oromucosal gel, based strictly on government regulatory documents.


Adverse Reaction Scope

The most commonly reported adverse effects are generally local and transient, occurring at the site of application. Regulatory classifications indicate that local irritation and a transient burning or stinging sensation in the mouth are common occurrences.

While systemic absorption is minimal with correct use, the safety profile includes the risk of systemic hypersensitivity reactions associated with salicylates. These are generally classified as Not known (frequency) and include severe reactions such as anaphylactic reaction and angioedema (swelling beneath the skin and mucous membranes).


Population-Specific and Use-Related Safety

Reye's Syndrome Risk in Pediatrics: A primary safety consideration involves the use of salicylate-containing products in children. The medicine is contraindicated or requires specific caution for use in children and adolescents under 16 years of age, particularly if they have fever or are recovering from viral illnesses such as chickenpox or flu-like symptoms. This is due to the potential association between salicylates and the risk of Reye's syndrome, a rare but serious condition.

Late-Term Pregnancy: The use of NSAID-class drugs, including salicylates, is generally advised to be avoided from 30 weeks gestation onward due to the risks of premature closure of the fetal ductus arteriosus.

Safety Restrictions: The medicine is contraindicated in patients with a known hypersensitivity to salicylates or other NSAIDs, as well as those with active peptic ulceration. The risk of salicylate toxicity is also documented if the recommended dose is substantially exceeded or if the gel is used chronically.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Bucagel

This structured map is derived strictly from authoritative governmental regulatory documents regarding the overdose profile of Choline Salicylate.


Overdose Scope

Domain Official Regulatory Statement/Entity
Documented overdose presentations Systemic salicylate toxicity is defined by clinical manifestations including tinnitus (ringing in the ears), nausea, vomiting, hyperventilation, and confusion. Severe outcomes documented in regulatory guidance include convulsions (seizures), coma, and pulmonary oedema.
Physiological systems affected (as stated in label) Toxicity affects the acid-base balance (leading to respiratory alkalosis and subsequent metabolic acidosis) and the central nervous system (CNS).
Dose-related or exposure-related factors (if applicable) Ingestion of ge 150 mg/kg of the salicylate active ingredient is associated with a risk requiring urgent evaluation. Plasma concentrations above 350 mg/L are documented to be associated with toxicity.
Population-specific overdose notes (if applicable) Children and adolescents under 16 years of age are subject to a theoretical risk of developing Reye's syndrome from salicylate exposure. Vulnerable patients, including children, may require earlier definitive intervention.
Emergency-response statements (as written in official documents) Patients should receive symptomatic and supportive therapy or treatment for salicylate poisoning as necessary. Treatment may include activated charcoal and urinary alkalinisation. No specific antidote is known.
When immediate medical help is required (label-derived phrasing only) Seek immediate medical attention if overdose is suspected or if signs of salicylism (e.g., tinnitus, vomiting, or confusion) occur. Hospital evaluation and observation is required for symptomatic patients.

Overdose Classifications (High-Level)

Domain Official Regulatory Statement/Entity
Severity classification (as defined in official documents) Severity is defined by the progression of clinical signs and the degree of acid-base disturbances and CNS effects.
Regulatory basis (EMA / FDA / etc.) Based on the Summary of Product Characteristics (SmPC) and associated national health authority guidance.
Overdose-context constraints (as defined in official documents) Supportive care protocols require specific monitoring, including measurement of plasma salicylate concentrations and observation for a minimum period.

Resulting Overdose Structure

Official overdose statements:

  • The presence of tinnitus, hyperventilation, or confusion is documented in regulatory sources as an indication of systemic salicylate toxicity (salicylism).
  • Overdose may lead to severe outcomes including pulmonary oedema, convulsions, coma, or acute renal failure.
  • If an overdose is suspected, official guidance mandates that patients must seek immediate medical attention and be referred for hospital evaluation and observation.
  • Treatment protocols described in regulatory documents primarily involve symptomatic and supportive care, including the use of activated charcoal, urinary alkalinisation, and haemodialysis in severe cases.
  • Official labeling notes a theoretical risk of Reye's syndrome in children under 16 when using salicylate products.

Connection to the overall overdose profile (3 sentences): The regulatory profile details the systemic nature of toxicity and explicitly mandates that the onset of symptoms like tinnitus or vomiting is an immediate trigger to seek urgent help. The documented protocols specify the specialized elimination procedures needed, confirming that established systemic toxicity is a serious condition requiring professional intervention. The documented supportive management protocols also confirm that no specific antidote is known.

Therapeutic Uses of Bucagel

Bucagel (Choline Salicylate oromucosal gel) is commonly used for the targeted, symptomatic relief of discomfort and inflammation associated with common, minor lesions and sources of irritation within the oral cavity. Its function is primarily to offer focused, short-term supportive management for distressing local symptoms.


The product is generally applied in contexts where additional symptomatic support is needed for conditions presenting with localized discomfort, including mouth ulcers (canker sores), minor abrasions, denture sore spots, and irritation from orthodontic devices (braces). For patients experiencing these issues, Bucagel is relevant for easing challenging symptoms. “The formulation helps address symptom clusters that may become intense or disruptive, especially during routine functions like eating or speaking.” The primary benefit is that it generally assists with managing the temporary functional strain on daily stability, providing support that contributes to easing the overall symptom load of mechanical or inflammatory irritation.


Quick Fact: Relief for Localized Oral Pain and Inflammation

The medication is commonly used to help manage both the pain and tenderness (analgesic effect) and the localized redness and swelling (anti-inflammatory effect) that accompany these minor conditions. It assists with maintaining functional stability during symptomatic periods.

Eligibility and Restrictions for Use

Who Can and Cannot Use Bucagel?

Eligibility to use Bucagel (Choline Salicylate oromucosal gel) is strictly governed by its official classification as a salicylate derivative and is defined by the product’s regulatory labeling.

Populations Who Must Not Use the Medicine

The medicine is subject to absolute contraindications for several groups:

  • Hypersensitivity: Patients with known allergies to salicylates, Aspirin, or other NSAIDs.
  • Peptic Ulceration: Individuals with active or a history of recurrent peptic ulceration.
  • Age Restriction: In some countries (e.g., the UK), the product is contraindicated for all persons under 16 years of age due to the theoretical risk of Reye’s Syndrome. Infants under four months are contraindicated in all regions.
  • Viral Illness: Children under 16 years with a concurrent viral illness (such as Chicken Pox or Influenza) must not use this product.

Populations with Conditional Eligibility

Population Regulatory Status
Adults (16+) Approved for general use.
Older Adults Approved; no dosage modification required.
Pregnancy/Lactation Consultation with a healthcare professional is mandatory; use is generally advised to be avoided at term (late stage of pregnancy).
Children 4 months+ Conditional approval in some regions, with strictly limited application amounts and use prohibited during viral illness.

What should I know about interactions with other medicines?

Official Regulatory Interaction Profile

The interaction profile for Bucagel (Choline Salicylate) is determined by the salicylate component's known systemic effects, despite the topical formulation. Regulatory documents define interaction constraints based on pharmacodynamic effects and additive risks.

Category Officially Documented Interaction Entities
Contraindicated Combinations Acetylsalicylic Acid (Aspirin); Other Salicylates
Pharmacodynamic Interactions Anticoagulants; Uricosuric Agents; Other Systemic NSAIDs
Other Substance Interactions Alcohol; Tobacco
Population Restriction Individuals under 16 years of age

Official Interaction Statements

Co-administration with Acetylsalicylic Acid (Aspirin) or other salicylates is restricted and should be avoided due to the potential for cumulative salicylate exposure. This product's salicylate content may enhance the effect of co-administered anticoagulants and may inhibit the action of uricosuric agents, effects documented in regulatory prescribing information. The concurrent use of Alcohol or Tobacco is noted to augment the risk of gastrointestinal side effects.

Regarding specific patient groups, regulatory authorities have mandated that oral salicylate gels are not indicated for use in individuals under 16 years of age. This population-specific restriction is a precautionary measure tied to the inherent risks associated with systemic salicylate exposure.

Mechanism of Action

How Bucagel Works

Bucagel's action is achieved through three distinct, localized mechanistic domains that collectively adjust the local physiological state.


Local Numbing: Blocking Nerve Signals

This domain describes the drug's primary action as an inhibitor targeting voltage-gated sodium channels ( Na^+ channels) on peripheral nerve membranes. By blocking sodium ion influx, the drug suppresses the generation of nerve impulses, leading to a reversible cessation of sensory signaling that alters afferent nerve communication.


Targeted Microbial Disruption

This section covers the drug's role as a disruptor that interacts with the cell membrane lipids and proteins of local microorganisms. This direct action compromises the structural integrity of these cells, resulting in a limited viability and proliferation of local microorganisms, which influences local biochemical dynamics.


Tissue Modulation

This mechanism acts as a modulator that influences components of the local tissue barrier. By engaging mechanisms related to cellular structure and local environmental factors, the drug influences processes related to local tissue regulation, contributing to altered local cellular activity.

Dosage and Administration Information

The use of Bucagel (Choline Salicylate Oromucosal Gel) is based on specific administration instructions. The medicine is strictly for topical application to the oral mucosa, meaning it is applied directly inside the mouth and must not be swallowed.

Administration and Dosing

The standard administration method requires applying the gel using a clean finger and gently massaging it onto the affected sore area.

The dosage differs by age group:

  • Adults (and Children over 16): The measure is approximately half an inch or one centimetre (1 cm) of the gel.
  • Children (from four months): A smaller, pea-sized amount of gel (approx 0.5 cm) should be used.

Frequency and Duration

The dosing schedule is constrained by both minimum interval and daily maximum limits. An application must be separated by at least three hours. Individuals must not exceed six doses within any 24-hour period.

Bucagel is intended for short-term, symptomatic management. If symptoms do not show improvement after seven days of use, the treatment should be discontinued. For special circumstances, such as irritation from dentures, the gel must be applied to the gums or sore spot, and the dentures must be left out for at least 30 minutes before re-insertion; the product must never be applied directly to the dentures.

Population-Specific Guidelines

Typically no dose modification is necessary for older adults. The product is not suitable for infants under four months of age. If a dose is missed, a new dose should be applied ensuring the proper time interval is respected; a double dose must never be applied to compensate for a missed one.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bucagel


Evidence for use in Minor Oral Ulcers and Sores

Studies were conducted to explore the use of Choline Salicylate oromucosal gel for oral ulcers and sores, including randomized controlled trials. These investigations were generally applied in research exploring how symptoms change over time and were relevant in trials assessing short-term or episodic symptom patterns. Researchers monitored adult populations presenting with common non-traumatic ulcers, such as canker sores. The principal outcomes measured included changes in pain intensity (a patient-reported outcome describing perceived discomfort) and objective measurements of ulcer size and data related to the time interval until symptoms were no longer present.

The studies monitored and reported measurements of pain intensity and the time intervals required for the observed lesions to reach clinical resolution. Findings describe patterns observed in the studies related to how symptoms evolved in the observed populations over defined time intervals. Research highlights changes measured during the study period, helping to contextualize how patients reported their experience during periods of increased symptom activity.

Evidence for use in Mucosal Irritation from Dental Devices

Studies were conducted to explore the use of the gel in conditions associated with acute or disruptive episodes, such as irritation and sore spots caused by dental prostheses or orthodontic devices. These clinical investigations were applied in studies examining patient-reported experiences, with outcomes linked to inflammatory or irritative states. The populations studied typically included older adults adjusting to new dentures or individuals with temporary oral devices.


Key Studies & References

  1. Oral salicylate gels: not for use in those younger than age 16 years (MHRA/GOV.UK Drug Safety Update)
  2. Topical oral choline salicylate gels - safety in children (Medsafe, New Zealand)

Frequently Asked Questions (FAQ)

Common questions about Bucagel (FAQ)


Q: How is Bucagel different from a standard topical mouth pain ointment?

Official documents describe Bucagel as a topical Non-Steroidal Anti-Inflammatory Drug (NSAID) that provides localized pain relief.

Unlike general ointments, this medicine acts on the oral tissue through three specific mechanisms, including blocking nerve signals to provide the effect of local numbing.


Q: Can Bucagel be used for mouth sores other than the primary condition it treats?

Official product information indicates that Bucagel is used for the relief of pain and discomfort from several common oral issues.

These indications include common mouth ulcers, cold sores, and sore spots caused by dental devices.


Q: Is it true that Bucagel’s delivery method helps it bypass the liver's first-pass metabolism?

According to official regulatory information, this medicine is a topical preparation designed for local action on the oral mucosa.

This is noted to result in minimal systemic exposure compared to swallowed tablets or capsules.


Q: What unusual symptoms should prompt a person to stop using Bucagel and seek help?

Official documents list symptoms that may warrant immediate medical attention, such as swelling of the face, lips, tongue, or throat, which can be signs of a severe allergic reaction.

Caution is also warranted if there are any signs of internal bleeding, such as bloody or black, tar-like stools.


Q: Have there been studies on the safety of using Bucagel for extended periods?

Bucagel is officially intended for short-term, symptomatic management for up to seven days.

Regulatory warnings state that excessive or prolonged use beyond the labeled duration can be harmful and is generally advised to be avoided in official product information.


Q: Is it necessary to avoid eating or drinking for a certain time after applying the gel?

Regulatory guidance advises avoiding eating and drinking immediately after application.

This recommendation is made to ensure the gel remains in contact with the affected area for a sufficient period.


Q: How soon after application can I safely swallow or drink liquids?

The official label advises against eating and drinking immediately after use to allow for contact with the affected area.

Specific instructions for dental appliances recommend waiting at least 30 minutes before reinserting the appliance.


Q: Does Bucagel contain any common allergens like gluten, lactose, or specific dyes?

Official product labeling confirms the presence of excipients such as alcohol, saccharin, and cetalkonium chloride as a preservative.

For a comprehensive list of all non-active ingredients, referencing the package leaflet or prescribing information is recommended.


Q: Is the feeling of a metallic taste or irritation in the mouth a commonly reported initial issue?

According to official safety information, the commonly reported adverse effects include a feeling of local irritation, a burning sensation, and reported taste changes.

These effects are generally transient and occur at the application site.


Q: What should I do if the irritation from Bucagel seems to be getting worse?

Regulatory advice states that if irritation or any other side effect appears severe or begins to worsen, stopping the use of the medication immediately is warranted.

A healthcare professional should be consulted for further guidance.


Q: Does Bucagel interact with common dental work like braces, fillings, or dentures?

Official documents provide specific instructions for use with dentures and state the medicine is indicated for sore spots caused by orthodontic devices.

However, no specific warnings regarding interaction with metal fillings are noted in the regulatory information.


Q: How long does the primary effect of Bucagel typically last?

Regulatory sources report that the localized analgesic effect of the topical gel typically lasts for up to two to three hours.


Q: When is the earliest time I should notice the effects of Bucagel after application?

Official information and studies indicate that pain relief can begin to be effectively felt within two to three minutes of application.

This rapid onset is due to the medicine's localized action.


Q: Is there official information about what happens if a small amount of Bucagel is accidentally swallowed?

Bucagel is strictly for topical use only, and swallowing is noted as potentially harmful.

Ingesting amounts substantially exceeding the dose can lead to documented signs of salicylate toxicity, such as ringing in the ears, dizziness, or confusion.


Q: Are there any official restrictions on driving or operating heavy machinery while using Bucagel?

Official information generally suggests that Choline Salicylate oromucosal gel does not impair the ability to drive or operate machinery.


Q: What is the typical percentage strength of the active ingredient in Bucagel?

The active ingredient, Choline Salicylate, is commonly formulated in a concentration of 8.7% or 87 mg/g in the oromucosal gel.


Q: What is the general recommendation for using Bucagel if a person has liver or kidney issues?

According to official guidelines, caution is generally warranted for patients with severe renal impairment or pre-existing hepatic impairment.

This is due to the systemic absorption of the salicylate component.


Q: Can I apply the gel if the affected area is bleeding slightly or has a wound?

The medicine is strictly contraindicated in patients with active peptic ulceration.

Caution is generally warranted for conditions involving active or recent gastrointestinal bleeding or lesions due to the presence of the salicylate component.

How should Bucagel be stored and disposed of?

Official Storage and Disposal Instructions

Bucagel (Choline Salicylate oromucosal gel) must be stored according to its official regulatory labeling to ensure stability.

Storage Requirement Official Mandate
Temperature Store below 25 C; do not freeze.
Protection Keep the tube tightly closed; store in the original container to protect from light.
Child Safety Keep out of the sight and reach of children.
Stability Do not use past the expiry date.

Unused or expired gel must not be disposed of via wastewater or household waste. Disposal must be done in accordance with local pharmaceutical waste requirements, often by returning the medicine to a pharmacy.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bucagel found in:

A-Z Index: